Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00241514|
Recruitment Status : Completed
First Posted : October 19, 2005
Last Update Posted : January 21, 2011
|Condition or disease||Intervention/treatment||Phase|
|GERD||Drug: Esomeprazole||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||334 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs|
|Study Start Date :||February 2001|
|Actual Primary Completion Date :||February 2003|
|Actual Study Completion Date :||February 2003|
- To assess the efficacy of esomeprazole 40 mg orally q.d. versus placebo orally q.d.
- and 20 mg q.d. versus placebo orally q.d. through 6 months of treatment for the
- prevention of relapse of upper GI symptom associated with NSAID use in patients
- receiving daily NSAID therapy.
- To assess the safety and tolerability of esomeprazole 40 mg orally q.d. versus placebo orally q.d. and 20 mg orally q.d. versus placebo orally q.d. when administered for 6 months to patients receiving daily NSAID therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00241514
|Study Director:||AstraZeneca Nexium Medical Sciences Director, MD||AstraZeneca|